ArticleInternational journal of oncology2012
Inhibition of tumor cell surface ATP synthesis by pigment epithelium-derived factor: implications for antitumor activity.
Article in International journal of oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Pigment Epithelium-Derived Factor Inhibits Cell Motility and p-ERK1/2 Signaling in Intrahepatic Cholangiocarcinoma Cell Lines.Biology · 2025Article
- Receptors that bind to PEDF and their therapeutic roles in retinal diseases.Frontiers in endocrinology · 2023Review
- PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis.Channels (Austin, Tex.) · 2021Article
- Natural products and other inhibitors of FEuropean journal of medicinal chemistry · 2020Review
- Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy.Experimental eye research · 2020Article
- Mitochondrial ATP synthase regulates corpus cavernosum smooth muscle cell functionExperimental and therapeutic medicine · 2020Article
- Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche.Nature communications · 2017Article
- PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.PloS one · 2017Article
- A humanized chimeric antibody Hai178 targeted to the β subunit of F1F0 ATP synthase.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Temporal Phosphoproteome Dynamics Induced by an ATP Synthase Inhibitor Citreoviridin.Molecular & cellular proteomics : MCP · 2015Article
- Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor.The Journal of biological chemistry · 2015Article
- Recombinant pigment epithelium-derived factor PEDF binds vascular endothelial growth factor receptors 1 and 2.In vitro cellular & developmental biology. Animal · 2015Article
- PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases.Clinical science (London, England : 1979) · 2015Review
- ATP release mechanisms of endothelial cell-mediated stimulus-dependent hyperalgesia.The journal of pain · 2014Article
- Revisiting the matricellular concept.Matrix biology : journal of the International Society for Matrix Biology · 2014Review
- Pigment epithelium-derived factor (PEDF) prevents retinal cell death via PEDF Receptor (PEDF-R): identification of a functional ligand binding site.The Journal of biological chemistry · 2013Article
- The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential.Nature reviews. Cancer · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Recently, we have shown that the antiangiogenic pigment epithelium-derived factor (PEDF) can bind the catalytic β-subunit of F1-ATP synthase and inhibit endothelial cell surface ATP synthase activity. This factor can additionally restrict tumor growth, invasion and metastasis, and can directly induce death on several tumor cell types. Active cell surface ATP synthase is also present in certain tumor cells and its ATP product is considered a stimulus for tumor growth. The present study aimed to elucidate the biological implications of the interactions between the extracellular PEDF and tumor cell surface ATP synthase. Incubation of T24 human urinary bladder carcinoma cells in media containing human recombinant PEDF protein for 48-96 h dramatically decreased cell viability in a concentration-dependent fashion as monitored by real-time cell impedance with a microelectronic system, microscopic imaging and biomarkers of live cells. Intact tumor cells exhibited cell surface ATP synthesis activity, which was inhibited by piceatannol, a specific inhibitor of F1/F0-ATP synthase. Immunoblotting revealed that the β subunit of F1-ATP synthase was present in plasma membrane fractions of these cells. Interestingly, pre-incubation of tumor cells with PEDF inhibited the activity of cell surface ATP synthase in a concentration-dependent fashion. The PEDF-derived peptide 34-mer decreased tumor cell viability and inhibited extracellular ATP synthesis to the same extent as full-length PEDF. Moreover, ATP additions attenuated both the PEDF-mediated decrease in tumor cell viability and the inhibition of endothelial cell tube formation. The results lead to conclude that PEDF is a novel inhibitor of tumor cell surface ATP synthase activity that exhibits a cytotoxic effect on tumor cells, and that the structural determinants for these properties are within the peptide region 34-mer of the PEDF polypeptide. The data strongly suggest a role for the interaction between the 34-mer region of PEDF and tumor cell-surface ATP synthase in promoting tumor cell death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.